Results 291 to 300 of about 787,124 (352)

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Advanced Science, EarlyView.
Relapsed and refractory multiple myeloma remains a major clinical challenge. This study shows that FOXM1 contributes to resistance against BH3 mimetics in multiple myeloma cells. The FOXM1 inhibitor NB73 enhances the effectiveness of BH3 mimetics by reducing FOXM1 expression and suppressing the MYC pathway.
Zhi Wen, Yidan Wang, Kathryn C. Fox, Adam M. Bissonnette, Luke F. Moat, Terrie E. Kitchner, Kelsey Springstroh, Sung Hoon Kim, Dagna S. Sheerar, Patcharon Tanawattanacharoen, Chady A. Leon, Seth O. Fagbemi, John A. Katzenellenbogen, Scott J. Hebbring, Benita S. Katzenellenbogen, Siegfried Janz, Adedayo A. Onitilo   +16 more
wiley   +1 more source

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib. [PDF]

J Cell Mol Med
Broccoli A, Del Re M, Danesi R, Zinzani PL.   +3 more
europepmc   +1 more source

Solving the Amyloid Paradox: Unveiling the Complex Pathogenicity of Amyloid Fibrils

Aggregate, EarlyView.
This review addresses the gap between strong evidence for the involvement of amyloid fibrils in neurodegeneration and the failure of anti‐amyloid therapies, a phenomenon herein termed the “amyloid paradox.” To address this paradox, we provide a comprehensive summary of the current understanding of fibrils' pathogenic properties and mechanisms ...
Maksim I. Sulatsky, Olesya V. Stepanenko, Olga V. Stepanenko, Anna I. Sulatskaya   +3 more
wiley   +1 more source

Kidney injury: the spleno-renal connection and splenic tyrosine kinase. [PDF]

J Nephrol
Almasry Y, Alodhaibi I, Nammor T, Lerman A, Lerman LO, Zhu XY.   +5 more
europepmc   +1 more source

Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis. [PDF]

World J Surg Oncol
Tian H, Wan C.
europepmc   +1 more source

A Novel Dual Bruton's Tyrosine Kinase/Janus Kinase 3 Inhibitor Wj1113 and its Therapeutic Effects on Rheumatoid Arthritis. [PDF]

MedComm (2020)
Zhang C, Lai F, Gong H, Li S, Xiang N, Que L, Xue N, Hao M, Zhou E, Wang X, Liang T, Jin J.   +11 more
europepmc   +1 more source

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis. [PDF]

Blood Adv
Shadman M, Brown JR, Mohseninejad L, Yang K, Burnett H, Neupane B, Williams R, Lamanna N, O'Brien SM, Tedeschi A, Tam CS.   +10 more
europepmc   +1 more source

A Fast Method to Monitor Tyrosine Kinase Inhibitor Mechanisms. [PDF]

J Med Chem
Fernández A, Gairí M, González MT, Pons M.   +3 more
europepmc   +1 more source

Tyrosine kinase inhibitors modulate the expression of peroxiredoxins 1 and 2 in chronic myeloid leukemia cells. [PDF]

Leuk Res Rep
Kazama H, Wang YH, Tanaka J.
europepmc   +1 more source